-
Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C).
Sandoz Pharma Ltd., Basel, Switzerland.
We have recently reported increased survival of dopaminergic substantia nigra neurons by inhibition of phosphodiesterase type IV enzymes. As a first step to unravel the involvement of PDE IV subtypes in this process, we isolated phosphodiesterase type IV cDNAs from human substantia nigra. One isolated partial cDNA clone was most homologous to the partially cloned rat and human PDE IV-C isogene. Distribution analysis revealed that the enzyme is expressed in various tissues but not in cells of the immune system. Isolation of the full-length human PDE IV-C isogene cDNA and expression in a PDE-deficient yeast strain resulted in functional complementation of the yeast heat shock response. Inhibition of the enzymatic activity by rolipram characterized this enzyme as a typical type IV phosphodiesterase.
PMID: 7843419 [PubMed - indexed for MEDLINE]
-
Cited by 6 PubMed Central articles
-
ReviewABCD of the phosphodiesterase family: interaction and differential activity in COPD.
Halpin DM.
Int J Chron Obstruct Pulmon Dis. 2008; 3(4):543-61.
[Int J Chron Obstruct Pulmon Dis. 2008]
-
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Trifilieff A, Keller TH, Press NJ, Howe T, Gedeck P, Beer D, Walker C.
Br J Pharmacol. 2005 Apr; 144(7):1002-10.
[Br J Pharmacol. 2005]
-
Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS.
Br J Pharmacol. 1999 Dec; 128(7):1393-8.
[Br J Pharmacol. 1999]
- » See all...